Neovacs and Centurion sign licence agreement for lupus treatment IFNalpha Kinoid in Turkey
French biotechnology company Neovacs has signed an exclusive licence agreement with Centurion Pharma for IFNalpha Kinoid to treat patients with lupus in Turkey.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | France Health | Lupus | Middle East Health | Pharmaceuticals | Turkey Health